Earlier this week we highlighted how click chemistry technology has enabled the development of a protodrug platform with inert polymers for more targeted delivery of chemotherapeutic drugs.
Similarly, another related approach we can consider to reduce unwanted adverse events is the prodrug concept. In this situation, a potent chemotherapy is activated in the tumour where it is most needed thereby reducing the toxic effects on normal cells and improving tolerability for people receiving the therapy.
Can prodrug technology deliver potent alkylator chemotherapy in a much more targeted fashion in the tumour?
One of the well known challenges and limitations associated with standard alkylating chemotherapies has always been the indiscriminate toxicities resulting from systemic administration – they impact both cancer cells and normal cells with impunity.
What if we could develop a more targeted chemotherapy approach?
This might be useful for some people with advanced cancer where a modicum of disease control is needed, so how would we go about achieving this aim?
Here’s one way to potentially accomplish the task…
To learn more about these insights and get a heads up on our latest oncology expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Before we move on to the Society for Immunotherapy of Cancer (SITC) meeting later this week, it’s time to wrap up the exciting AACR-NCI-EORTC molecular targets conference, which along with the CRI-CIMT-EATI-AACR international cancer immunotherapy conference in Mainz, have been my two favourite oncology meetings of the year so far.
Who would have predicted that back in January?
A scoot around the narrow #Targets17 poster hall…
It would be hard not to close out coverage without a popular Gems from the Poster Halls post.
Typically, we have focused this theme from cancer conferences around the following:
- A new target
- An interesting molecule
- Intriguing basic or translational science of note
- A particular tumour type
- Insightful sentiments from thought leaders
In this latest version, we have examples of each. We also have my favourite quote and discussion from the meeting, which perhaps not surprisingly, comes from a CAR T cell therapy discussion.
To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.